Literature DB >> 21520273

Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.

Marinela Capanu1, Patrick Concannon, Robert W Haile, Leslie Bernstein, Kathleen E Malone, Charles F Lynch, Xiaolin Liang, Sharon N Teraoka, Anh T Diep, Duncan C Thomas, Jonine L Bernstein, Colin B Begg.   

Abstract

Current evidence suggests that the genetic risk of breast cancer may be caused primarily by rare variants. However, while classification of protein-truncating mutations as deleterious is relatively straightforward, distinguishing as deleterious or neutral the large number of rare missense variants is a difficult on-going task. In this article, we present one approach to this problem, hierarchical statistical modeling of data observed in a case-control study of contralateral breast cancer (CBC) in which all the participants were genotyped for variants in BRCA1 and BRCA2. Hierarchical modeling permits leverage of information from observed correlations of characteristics of groups of variants with case-control status to infer with greater precision the risks of individual rare variants. A total of 181 distinct rare missense variants were identified among the 705 cases with CBC and the 1,398 controls with unilateral breast cancer. The model identified three bioinformatic hierarchical covariates, align-GV, align-GD, and SIFT scores, each of which was modestly associated with risk. Collectively, the 11 variants that were classified as adverse on the basis of all the three bioinformatic predictors demonstrated a stronger risk signal. This group included five of six missense variants that were classified as deleterious at the outset by conventional criteria. The remaining six variants can be considered as plausibly deleterious, and deserving of further investigation (BRCA1 R866C; BRCA2 G1529R, D2665G, W2626C, E2663V, and R3052W). Hierarchical modeling is a strategy that has promise for interpreting the evidence from future association studies that involve sequencing of known or suspected cancer genes.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21520273      PMCID: PMC3111904          DOI: 10.1002/gepi.20587

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  33 in total

1.  Hierarchical modeling of linkage disequilibrium: genetic structure and spatial relations.

Authors:  David V Conti; John S Witte
Journal:  Am J Hum Genet       Date:  2003-01-13       Impact factor: 11.025

2.  Using hierarchical modeling in genetic association studies with multiple markers: application to a case-control study of bladder cancer.

Authors:  Rayjean J Hung; Paul Brennan; Christian Malaveille; Stefano Porru; Francesco Donato; Paolo Boffetta; John S Witte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-06       Impact factor: 4.254

3.  Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function.

Authors:  Tong Xi; Irene M Jones; Harvey W Mohrenweiser
Journal:  Genomics       Date:  2004-06       Impact factor: 5.736

4.  A note on the estimation of relative risks of rare genetic susceptibility markers.

Authors:  C B Begg; M Berwick
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-02       Impact factor: 4.254

5.  A polymorphic stop codon in BRCA2.

Authors:  S Mazoyer; A M Dunning; O Serova; J Dearden; N Puget; C S Healey; S A Gayther; J Mangion; M R Stratton; H T Lynch; D E Goldgar; B A Ponder; G M Lenoir
Journal:  Nat Genet       Date:  1996-11       Impact factor: 38.330

6.  Hierarchical modeling of gene-environment interactions: estimating NAT2 genotype-specific dietary effects on adenomatous polyps.

Authors:  C C Aragaki; S Greenland; N Probst-Hensch; R W Haile
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-05       Impact factor: 4.254

7.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.

Authors:  S V Tavtigian; A M Deffenbaugh; L Yin; T Judkins; T Scholl; P B Samollow; D de Silva; A Zharkikh; A Thomas
Journal:  J Med Genet       Date:  2005-07-13       Impact factor: 6.318

8.  Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method.

Authors:  Marinela Capanu; Colin B Begg
Journal:  Biometrics       Date:  2010-08-05       Impact factor: 2.571

9.  Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics.

Authors:  Clare L Scott; Mark A Jenkins; Melissa C Southey; Tracey A Davis; Jennifer A Leary; Douglas F Easton; Kelly-Anne Phillips; John L Hopper
Journal:  Hum Genet       Date:  2003-02-25       Impact factor: 4.132

10.  Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study.

Authors:  Jonine L Bernstein; Bryan Langholz; Robert W Haile; Leslie Bernstein; Duncan C Thomas; Marilyn Stovall; Kathleen E Malone; Charles F Lynch; Jørgen H Olsen; Hoda Anton-Culver; Roy E Shore; John D Boice; Gertrud S Berkowitz; Richard A Gatti; Susan L Teitelbaum; Susan A Smith; Barry S Rosenstein; Anne-Lise Børresen-Dale; Patrick Concannon; W Douglas Thompson
Journal:  Breast Cancer Res       Date:  2004-03-09       Impact factor: 6.466

View more
  14 in total

1.  Incorporating model uncertainty in detecting rare variants: the Bayesian risk index.

Authors:  Melanie A Quintana; Jonine L Berstein; Duncan C Thomas; David V Conti
Journal:  Genet Epidemiol       Date:  2011-08-26       Impact factor: 2.135

2.  A powerful and adaptive association test for rare variants.

Authors:  Wei Pan; Junghi Kim; Yiwei Zhang; Xiaotong Shen; Peng Wei
Journal:  Genetics       Date:  2014-05-15       Impact factor: 4.562

3.  Rare germline mutations in PALB2 and breast cancer risk: a population-based study.

Authors:  Marc Tischkowitz; Marinela Capanu; Nelly Sabbaghian; Lili Li; Xiaolin Liang; Maxime P Vallée; Sean V Tavtigian; Patrick Concannon; William D Foulkes; Leslie Bernstein; Jonine L Bernstein; Colin B Begg
Journal:  Hum Mutat       Date:  2012-02-15       Impact factor: 4.878

4.  False discovery rates for rare variants from sequenced data.

Authors:  Marinela Capanu; Venkatraman E Seshan
Journal:  Genet Epidemiol       Date:  2014-12-30       Impact factor: 2.135

5.  Some surprising twists on the road to discovering the contribution of rare variants to complex diseases.

Authors:  Duncan C Thomas
Journal:  Hum Hered       Date:  2013-04-11       Impact factor: 0.444

6.  Joint analysis for integrating two related studies of different data types and different study designs using hierarchical modeling approaches.

Authors:  Rui Li; David V Conti; David Diaz-Sanchez; Frank Gilliland; Duncan C Thomas
Journal:  Hum Hered       Date:  2013-01-18       Impact factor: 0.444

7.  Genetic predisposition to radiation-related cancer and potential implications for risk assessment.

Authors:  A J Sigurdson; D O Stram
Journal:  Ann ICRP       Date:  2012-08-22

8.  New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.

Authors:  Anna Kluska; Aneta Balabas; Agnieszka Paziewska; Maria Kulecka; Dorota Nowakowska; Michal Mikula; Jerzy Ostrowski
Journal:  BMC Med Genomics       Date:  2015-05-07       Impact factor: 3.063

9.  Integrated enrichment analysis of variants and pathways in genome-wide association studies indicates central role for IL-2 signaling genes in type 1 diabetes, and cytokine signaling genes in Crohn's disease.

Authors:  Peter Carbonetto; Matthew Stephens
Journal:  PLoS Genet       Date:  2013-10-03       Impact factor: 5.917

10.  Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.

Authors:  Derek So; Yann Joly
Journal:  Curr Pharmacogenomics Person Med       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.